Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 12
Submit an article Journal homepage
63
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study

Artur J. Racewicz NZOZ Centrum Medyczne, BiaBystok, PolandCorrespondence[email protected]
,
Pamela J. Schofield Procter & Gamble Pharmaceuticals, Mason, OH, USA
,
David L. Cahall sanofi-aventis, Bridgewater, NJ, USA
,
Gary A. Cline Procter & Gamble Pharmaceuticals, Mason, OH, USA
&
David E. Burgio Procter & Gamble Pharmaceuticals, Mason, OH, USA
Pages 3079-3089 | Accepted 24 Sep 2007, Published online: 12 Nov 2007

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Plamen Kinov & Mihail Boyanov. (2012) Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. International Journal of Women's Health 4, pages 167-174.
Read now
Kristina Casadei & Carolyn Becker. (2009) Once-monthly risedronate for postmenopausal osteoporosis. International Journal of Women's Health 1, pages 1-9.
Read now

Articles from other publishers (3)

George A Wells, Shu-Ching Hsieh, Carine Zheng, Joan Peterson, Wenfei Liu, Shannon E Kelly & Peter Tugwell. (2022) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Yong Ho Cho, Kyung Hyun Bae, Dong Ryul Lee & Jungun Lee. (2020) Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study. Korean Journal of Family Medicine 41:5, pages 339-345.
Crossref
Louis-Georges Ste-Marie, Jacques P. Brown, John F. Beary, Ellen Matzkin, Lynn M. Darbie, David E. Burgio & Artur J. Racewicz. (2009) Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Clinical Therapeutics 31:2, pages 272-285.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.